PuSH - Publication Server of Helmholtz Zentrum München

Mc Guire, C.* ; Elton, L.* ; Wieghofer, P.* ; Staal, J.* ; Voet, S.* ; Demeyer, A.* ; Nagel, D. ; Krappmann, D. ; Prinz, M.* ; Beyaert, R.* ; van Loo, G.*

Pharmacological inhibition of MALT1 protease activity protects mice in a mouse model of multiple sclerosis.

J. Neuroinflamm. 11:124 (2014)
Publ. Version/Full Text DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
BACKGROUND: The paracaspase mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is crucial for lymphocyte activation through signaling to the transcription factor NF-κB. Besides functioning as a scaffold signaling protein, MALT1 also acts as a cysteine protease that specifically cleaves a number of substrates and contributes to specific T cell receptor-induced gene expression. Recently, small molecule inhibitors of MALT1 proteolytic activity were identified and shown to have promising anticancer properties in subtypes of B cell lymphoma. However, information on the therapeutic potential of small compound inhibitors that target MALT1 protease activity in autoimmunity is still lacking. METHODS: The present study aimed to elucidate whether MALT1 protease inhibitors are also useful in the treatment of lymphocyte-mediated autoimmune pathologies such as multiple sclerosis (MS). For this, we studied the therapeutic potential of a recently identified inhibitor of MALT1 protease activity, the phenothiazine derivative mepazine, in the context of experimental autoimmune encephalomyelitis (EAE), the main animal model for MS. RESULTS: We demonstrate that administration of mepazine prophylactically or after disease onset, can attenuate EAE. Importantly, while complete absence of MALT1 affects the differentiation of regulatory T (Treg) cells in vivo, the MALT1 protease inhibitor mepazine did not affect Treg development. CONCLUSIONS: Altogether, these data indicate that small molecule inhibitors of MALT1 not only hold great promise for the treatment of B cell lymphomas but also for autoimmune disorders such as MS.
Altmetric
Additional Metrics?
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Corresponding Author
Keywords Multiple Sclerosis ; Experimental Autoimmune Encephalomyelitis ; Malt1 ; Mepazine ; Demyelination; Nf-kappa-b; Autoimmune-mediated Demyelination; Paracaspase Malt1; Abc-dlbcl; Activation; Cleavage; Lymphoma; Immune; A20
ISSN (print) / ISBN 1742-2094
e-ISSN 1742-2094
Quellenangaben Volume: 11, Issue: 1, Pages: , Article Number: 124 Supplement: ,
Publisher BioMed Central
Publishing Place London
Non-patent literature Publications
Reviewing status Peer reviewed
Institute(s) Research Unit Signaling and Translation (SAT)